U.S. Markets open in 4 hrs 49 mins

Pfizer Caving to Trump Has Wall Street Asking Who's Next

Cristin Flanagan
Pfizer Caving to Trump Has Wall Street Asking Who's Next

Pfizer’s decision to delay planned drug price hikes after President Trump attacked the company on Twitter may cause another shakeout throughout the health-care industry. Analysts at Goldman Sachs, Morgan Stanley and SunTrust expect other drugmakers will have to show more restraint on price increases, and say drug distributors may also find themselves under pressure. Height Capital Markets earlier cautioned about the risk to pharmacy-benefit managers, saying that Pfizer’s move ups the ante for the White House to propose policy changes on the use of rebates.